Onxeo

About:

Onxeo is a biotechnology company that develops drugs for oncology.

Website: http://onxeo.com

Twitter/X: onxeo_

Top Investors: Bpifrance, Invus, Nice & Green SA, Oséo, Financière de la Montagne

Description:

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.